Anti-diabetic compounds from the seeds of Psoralea corylifolia
Gaohui Zhu1, Yanhong Luo1, Xuejiao Xu1
1Department of Endocrinology, and China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Abstract:
A new aurone named (2Z)-2-[(4'-hydroxyphenyl) methylene]-6-hydroxy-7-prenyl-3(2H)-benzofurane (1), two new flavonoids named (2S)-7-methoxy-6-(2-hydroxy-3-methylbut-3-en-1-yl)-2-(4-hydroxyphenyl)chroman-4-one (2), (2S)-4'-hydroxyl-7-hydroxymethylene-6-(2″,3″-epoxy-3″-methylbutyl)flavanone (3), and a new coumestan named bavacoumestan E (4), together with eleven known compounds (5-15), were isolated from the seeds of Psoralea corylifolia. The chemical structures were elucidated by spectroscopic and physico-chemical analyses. All isolates were evaluated for in vitro inhibitory activity against DGAT, PTP1B and α-glucosidase. Compounds 1, 2 and 3 showed potential inhibitory activities on DGAT1 with IC50 values of 35.2 ± 1.3, 51.3 ± 1.1 and 43.4 ± 0.7 μM, respectively. Compounds 6 and 8 displayed the significant inhibitory activities on α-glucosidase with IC50 value of 28.0 and 23.0 μM, respectively.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Sulfonylureas
Antihypertensive Drugs: Direct Renin Inhibitors
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides

